

Rapid and efficient purification and refolding of a (histidine)₆-tagged recombinant protein produced in *E. coli* as inclusion bodies

Summary

This Application Note describes the purification and refolding of a recombinant protein tagged with a (histidine)₆-tag at its N-terminus. Using a simple but efficient purification and refolding procedure, a protein initially produced as intracellular inclusion body material in *Escherichia coli* is converted to soluble protein exhibiting the desired activity. This protocol has been used successfully for several different (histidine)₆-tagged recombinant proteins.

Introduction

Heterologous expression of foreign genes in *E. coli* can be engineered to lead to either intracellular accumulation of recombinant protein, or to secretion and accumulation in the periplasmic space. While the latter mode of expression is sometimes advantageous in terms of protein folding, solubility, and cysteine oxidation, the magnitude of protein production is generally much higher when intracellular expression is used (1).

However, recombinant protein accumulated intracellularly is frequently laid down in the form of inclusion bodies, insoluble aggregates of misfolded protein lacking biological activity (2,3,4,5). The high buoyant density of inclusion bodies facilitates their separation from soluble *E. coli* proteins and cell debris by differential centrifugation (4,6,7). Conventional methods for refolding of insoluble recombinant proteins include slow dialysis or dilution into a buffer of near-neutral pH (8). Gel filtration, ion exchange, or hydrophobic interaction chromatography have been used (9,10,11) to facilitate the refolding step.

Affinity tagging of the recombinant protein, for example by the addition of several consecutive histidine residues,

makes the efficient purification and refolding in a single chromatographic step possible. Since binding of the histidine tract to immobilized divalent metal ions can occur in the presence of a chaotropic agent (such as urea or guanidine hydrochloride) at high concentration, (histidine)₆-tagged inclusion body protein can be solubilized by chaotropic extraction and directly bound to an affinity matrix. Removal of contaminating proteins and refolding by exchange to non-denaturing buffer conditions can then be performed before elution of the protein from the column (12).

A general protocol for the purification and refolding of a (histidine)₆-tagged recombinant protein produced in *E. coli* is shown in Figure 1.




Fig 1. General scheme for the extraction, solubilization, and refolding of (histidine)₆-tagged recombinant proteins produced as inclusion bodies in *Escherichia coli* cells.



Disruption, wash, and isolation of inclusion bodies

Resuspend the cell paste from a 100 ml culture of *E. coli* expressing (histidine)₆-tagged recombinant protein in 4 ml 20 mM Tris-HCl pH 8.0. Disrupt the cells with sonication on ice (e.g., 4 × 10 sec.) and centrifuge at high speed for 10 min at 4°C. The pellet, containing the inclusion bodies, is resuspended in 3 ml cold 2 M urea, 20 mM Tris-HCl, 0.5 M NaCl, 2% Triton™ X-100 pH 8.0 and sonicated as above. Centrifuge at high speed for 10 min at 4°C. Subject the pellet to a second round of urea wash. At this stage the pellet material can be washed once in buffer lacking urea, and then stored frozen for later processing.

Solubilization and sample preparation

Resuspend the pellet in 5 ml 20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole, 6 M guanidine hydrochloride, 1 mM 2-mercaptoethanol pH 8.0. Stir for 30–60 min in room temperature and centrifugate 15 min at high speed, 4°C. Remove remaining particles by passing the sample through a 0.22 µm or 0.45 µm filter.

The optimal concentration of reducing 2-mercaptoethanol (0–5 mM) must be determined experimentally for each individual protein.

Proceed directly with the purification and refolding steps.

Preparation of the column

HiTrap™ Chelating HP 1 ml column is washed with 5 ml distilled water using a 5 ml syringe. Load 0.5 ml 0.1 M NiSO₄ and continue to wash with 5 ml distilled water. Equilibrate the column with 5–10 ml 20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole, 6 M guanidine hydrochloride, 1 mM 2-mercaptoethanol pH 8.0.

Purification and refolding

Loading and washing

Load the sample and wash the column with 10 ml 20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole, 6 M guanidine hydrochloride, 1 mM 2-mercapto-ethanol pH 8.0. Change the buffer to 20 mM Tris-HCl, 0.5 M NaCl, 20 mM imidazole, 1 mM 2-mercaptoethanol, 6 M urea pH 8.0 and wash with 10 ml.

Refolding

Refolding of the bound protein is performed using a linear 6–0 M urea gradient, starting with the wash buffer above and finishing at one without urea. A gradient volume of 30 ml or higher and a flow rate of 0.1–1 ml/min can be used, while the optimal renaturation rate should be determined experimentally for each protein. Continue to wash with 5 ml of buffer without urea after the gradient has come to its endpoint.

Elution

Elute the refolded recombinant protein using a 10–20 ml linear gradient starting with 20 mM Tris-HCl, 0.5 M NaCl, 20 mM imidazole, 1 mM 2-mercaptoethanol pH 8.0 and ending with the same buffer including 500 mM imidazole (Fig 2).

Fractions containing the eluted protein are pooled and subjected to buffer exchange using a HiTrap Desalting or PD-10 column, in order to remove imidazole. The refolded (histidine)₆-tagged protein is now ready for analysis of biological activity.

The choice of HiTrap column size depends on the amount of expressed protein.

While in this example a HiTrap Chelating HP 1 ml column is used, a HiTrap Chelating HP 5 ml is also available and should be used if the expected amount of recombinant protein exceeds 10 mg. For further scaling-up, Chelating Sepharose™ Fast Flow is available.

Column:	Ni ²⁺ -loaded HiTrap Chelating HP 1 ml
Sample:	N-terminal (histidine) ₆ -tagged recombinant protein produced in <i>E. coli</i>
Flow rates:	0.1–1 ml/min, sample loading and refolding 1 ml/min, wash and elution
Binding Buffer:	20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole, 6 M guanidine hydrochloride, 1 mM 2-mercaptoethanol pH 8.0
Washing buffer:	20 mM Tris-HCl, 0.5 M NaCl, 20 mM imidazole, 6 M urea, 1 mM 2-mercaptoethanol pH 8.0
Refolding buffer:	20 mM Tris-HCl, 0.5 M NaCl, 20 mM imidazole, 1 mM 2-mercaptoethanol pH 8.0
Refolding gradient:	30 ml
Elution Buffer:	20 mM Tris-HCl, 0.5 M NaCl, 500 mM imidazole, 1 mM 2-mercaptoethanol pH 8.0
Elution gradient:	10 ml
Fraction volumes:	3 ml sample loading, wash and refolding 1 ml elution




Fig 2. On-column refolding and purification of a (histidine)₆-tagged protein from inclusion bodies on Ni²⁺-charged HiTrap Chelating HP.

Column: Superdex™ 75 HR 10/30 (V_r: 24 ml)
Sample: 0.2 ml purified and refolded N-terminal (histidine)₆-tagged recombinant protein eluted from HiTrap Chelating HP 1 ml
Buffer: 0.15 M NaCl
Flow rate: 0.5 ml/min
Fraction volume: 1 ml




Fig 3. Analysis using gel filtration of refolded (histidine)₆-tagged protein.

Gel: PhastGel™ Gradient 10–15
Sample pretreatment: Dilution 1:5 with 15% SDS, 30% 2-mercaptoethanol, 10 mM Tris, 1 mM EDTA
Sample volume: 1 µl
Molecular weight standard: Low Molecular Markers
Staining: Coomassie™, according to the manufacturer's standard protocol
Instrument: PhastSystem™




Fig 4. SDS-PAGE analysis.

Analysis

The aggregation state and purity of the refolded (histidine)₆-tagged recombinant protein eluted from HiTrap Chelating HP is checked by gel filtration on Superdex 75 HR 10/30 (Figure 3) and SDS-PAGE (Figure 4).

Regeneration and storage

Regenerate the column with 5 ml 6 M guanidine hydrochloride, 20 mM Tris-HCl, 0.5 M NaCl, 50 mM EDTA, pH 8.0. Wash with 10 ml distilled water followed by 10 ml 20% ethanol. Store the column in 20% ethanol.

References:

1. Marston, F.A.O. The purification of eucaryotic polypeptides synthesized in *Escherichia coli*. *Biochem J.* **240**, pp 1–12 (1986).
2. Williams, D.C., Van Frank, R.M., Muth, W.L., Burnett, J.P. Cytoplasmic inclusion bodies in *Escherichia coli* producing biosynthetic human insulin proteins. *Science* **215**, pp. 687–689 (1982).
3. Harris, T.J.R. Expression of eucaryotic genes in *E.coli*. In: Williamson, R.(Ed.) *Genetic Engineering*. Vol. 4, Academic Press, London, pp. 127–185 (1983).
4. Marston, F.A.O., Lowe, P.A., Doel, M., Schoemaker, J.M., White, S., Angal, S. Purification of calf prochymosin (prorennin) synthesized in *Escherichia coli*. *Bio/Technology* **2**, 800–804 (1984).
5. Lowe, P.E., et al. Solubilization, refolding and purification of eucaryotic proteins expressed in *E.coli*, in: *Protein purification: Micro to Macro*, A.R. Liss, Inc., pp. 429–442 (1987).
6. Kelley, R.F., Winkler, M.E. Folding of eucaryotic proteins produced in *Escherichia coli*. *Genetic Engineering* **12**, pp. 1–19 (1990).
7. Mitaki, A., King, J. Protein folding intermediates and inclusion body formation. *Bio/Technology* **7**, pp. 690–697 (1990).
8. Knuth, M.W., Burgess, R.R. Purification of proteins in the denaturated state, in: *Protein purification: Micro to Macro*, A. R. Liss, Inc., pp. 279–305 (1987).
9. Werner, M.H., Clore, G.M., Gronenborn, A.M., Kondoh, A., Fisher, R.J. Refolding proteins by gel filtration chromatography. *FEBS Letter* **345**, pp. 125–130 (1994).
10. Hoess, A., Arthur, A.K., Wanner, G., Fanning, E. Recovery of soluble, biologically active recombinant proteins from total bacterial lysates using ion exchange resin. *Bio/Technology* **6**, pp. 1214–1217 (1988).
11. Application Note: Purification and renaturation of recombinant proteins produced in *Escherichia coli* as inclusion bodies. GE Healthcare 18-1112-33.
12. Colangeli, R., Heijbel, A., Williams, A.M., Manca, C., Chan, J., Lyashchenko, K., Gennaro, M.L. Three-step purification of lipopolysaccharide-free polyhistidine-tagged recombinant antigens of *Mycobacterium tuberculosis*. *J of Chromatography B*, **714**, pp. 223–235 (1998).

Ordering information

Product	Quantity	Code No.	Related Products	Quantity	Code No.
HiTrap Chelating HP	5 × 1 ml	17-0408-01	HiTrap Desalting	5 × 5 ml	17-1408-01
HiTrap Chelating HP	1 × 5 ml	17-0409-01	HiPrep™ 26/10 Desalting	1 × 53 ml	17-5087-01
HiTrap Chelating HP	5 × 5 ml	17-0409-03	HiPrep 26/10 Desalting	4 × 53 ml	17-5087-02
			PD-10 Column	30	17-0851-01
			Chelating Sepharose Fast Flow	50 ml	17-0575-01
			Superdex 75 10/300 GL	1	17-5174-01
			Superdex 200 10/300 GL	1	17-5175-01
			HiLoad™ 16/60 Superdex 30 pg	1	17-1139-01
			HiLoad 26/60 Superdex 30 pg	1	17-1140-01
			HiLoad 16/60 Superdex 75 pg	1	17-1068-01
			HiLoad 26/60 Superdex 75 pg	1	17-1170-01
			HiLoad 16/60 Superdex 200 pg	1	17-1069-01
			HiLoad 26/60 Superdex 200 pg	1	17-1171-01
			XK 16/20 column	1	18-8773-01
			XK 16/40 column	1	18-8774-01
			XK 26/20 column	1	18-1000-72
			XK 26/40 column	1	18-8768-01

Related literature

	Code No.
Recombinant Protein Purification Handbook, Principles and methods	18-1142-75
Affinity Chromatography, Columns and Media Selection Guide	18-1121-86
Affinity Chromatography Handbook, Principles and Methods	18-1022-29
HiTrap Column Guide	18-1129-81

www.gelifesciences.com/hitrap
www.gelifesciences.com/protein-purification

GE Healthcare Bio-Sciences AB
 Björkgatan 30
 751 84 Uppsala
 Sweden

GE, imagination at work, and GE monogram are trademarks of General Electric Company.

AKTAdesign, Drop Design, HiLoad, HiPrep, HiTrap, PhastGel, PhastSystem, Sepharose, and Superdex, are trademarks of GE Healthcare companies.

All third party trademarks are the property of their respective owners.

Purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues may require a license under US patent numbers 5,284,933 and 5,310,663 and equivalent patents and patent applications in other countries (assignee: Hoffman La Roche, Inc).

© 1999-2007 General Electric Company – All rights reserved.
 First published Sep. 1999.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.

GE Healthcare Europe GmbH
 Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare UK Ltd
 Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp
 800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327, USA

GE Healthcare Bio-Sciences KK
 Sanken Bldg. 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo 169-0073, Japan

Asia Pacific T +85 65 62751830 F +85 65 62751829 • Australasia T +61 2 8820 8299 F +61 2 8820 8200 • Austria T 01 /57606 1613 F 01 /57606 1614 • Belgium T 0800 73 890 F 02 416 8206 • Canada T 1 800 463 5800 F 1 800 567 1008 • Central & East Europe T +43 1 972 720 F +43 1 972 722 750 • Denmark T +45 70 25 24 50 F +45 45 16 2424 • Eire T 1 800 709992 F +44 1494 542010 • Finland & Baltics T +358 9 512 3940 F +358 9 512 39439 • France T 01 69 35 67 00 F 01 69 41 98 77 • Germany T 0800 9080 711 F 0800 9080 712 • Greater China T +852 2100 6300 F +852 2100 6338 • Italy T 02 26001 320 F 02 26001 399 • Japan T 81 3 5331 9336 F 81 3 5331 9370 • Korea T 82 2 6201 3700 F 82 2 6201 3803 • Latin America T +55 11 3933 7300 F +55 11 3933 7304 • Middle East & Africa T +30 210 96 00 687 F +30 210 96 00 693 • Netherlands T 0800-82 82 82 1 F 0800-82 82 82 4 • Norway T +47 815 65 777 F +47 815 65 666 • Portugal T 21 417 7035 F 21 417 3184 • Russia, CIS & NIS T +7 495 956 5177 F +7 495 956 5176 • Spain T 902 11 72 65 F 935 94 49 65 • Sweden T 018 612 1900 F 018 612 1910 • Switzerland T 0848 8028 10 F 0848 8028 11 • UK T 0800 515 313 F 0800 616 927 • USA T +1 800 526 3593 F +1 877 295 8102



imagination at work